Sharekhan

Lasa Supergenerics Ltd

Mon 9/03/2026,15:42:26 | NSE : LASA

₹ 7.74-0.15 (-1.90%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 7.98

Previous Close

₹ 7.89

Volume

38082

Mkt Cap ( Rs. Cr)

₹38.78

High

₹ 7.99

Low

₹ 7.48

52 Week High

₹ 25.15

52 Week Low

₹ 7.18

Book Value Per Share

₹ 10.74

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Lasa Supergenerics Ltd

Your Vote -

Buy

26.92%

Hold

3.85%

Sell

69.23%

26.92%

26 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

NaN%

Sell Order Quantity

NaN%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Lasa Supergenerics Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Lasa Supergenerics posts Q3 net loss of Rs 2.55 cr

    13 Feb 2026, 4:10PM The company reported standalone net loss during the quarter stood at Rs 2.55 crore compared to net profit of Rs 5.49 crore in the previous year quarte
  • Lasa Supergenerics - Integrated Filing- Financial

    13 Feb 2026, 4:04PM Integrated filing
  • Lasa Supergenerics - Integrated Filing- Financial

    13 Feb 2026, 4:01PM Integated filing
  • Lasa Supergenerics - Integrated Filing For Quarter Ended December 31, 2025

    13 Feb 2026, 3:54PM Integrated filing for quarter ended December 31, 2025
  • Lasa Supergenerics - Outcome of Board Meeting

    13 Feb 2026, 3:43PM Lasa Supergenerics Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
  • Lasa Supergenerics - Results For Quarter Ended 31St December 2025

    13 Feb 2026, 3:37PM Results for quarter ended 31st December 2025
  • Lasa Supergenerics - Outcome of Board Meeting

    13 Feb 2026, 3:22PM Lasa Supergenerics Limited has informed the Exchange regarding Board meeting held on February 13, 2026.
  • Lasa Supergenerics - Board Meeting Outcome for Outcome Of Board Meeting For Quarter Ended 31St December , 2025

    13 Feb 2026, 3:20PM Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Boar
  • Lasa Supergenerics - Board Meeting Intimation for For The Quarter Ended December 31, 2025

    3 Feb 2026, 4:29PM Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider a
  • Lasa Supergenerics - Structural Digital Database

    20 Jan 2026, 5:32PM Structure Digital Database
  • Lasa Supergenerics has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2025

    19 Jan 2026, 4:40PM As of December 2025, 53.65% is owned by Indian Promoters and 46.35% by Public. <p align=justify> Top Promoter holding highest number of shares of Lasa
  • Lasa Supergenerics - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    15 Jan 2026, 1:32PM Lasa Supergenerics Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Lasa Supergenerics - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    15 Jan 2026, 1:13PM Certificate under Reg 74 (5) of SEBI (DP) Regulations, 2018
  • Lasa Supergenerics - Outcome of Board Meeting

    2 Jan 2026, 4:22PM Lasa Supergenerics Limited has informed the Exchange regarding Board meeting held on January 02, 2026.
  • Lasa Supergenerics - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. January 02, 2026\r\n1. Appointment O

    2 Jan 2026, 4:19PM Pursuant to Regulation 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Di
  • Lasa Supergenerics - Trading Window

    29 Dec 2025, 4:20PM Lasa Supergenerics Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulation
  • Lasa Supergenerics - Appointment of Company Secretary and Compliance Officer

    15 Dec 2025, 4:50PM We wish to inform you that Mrs. Mitti Jain is hereby appoitned as Company secretary and Compliance Officer of the Company
  • Lasa Supergenerics - Cessation

    11 Dec 2025, 5:52PM Lasa Supergenerics Limited has informed the Exchange regarding Cessation of MR. PRATHMESH CHALKE as Executive Director of the company w.e.f. December
  • Lasa Supergenerics - Announcement under Regulation 30 (LODR)-Cessation

    11 Dec 2025, 5:46PM We would llike to inform you that Mr. Prathmesh Chalke tendered his resignation as Whole-time Director of the Company .
  • Lasa Supergenerics to start trial runs from Nov 25

    23 Nov 2017 , 12:13PM Lasa Supergenerics announces that it will start its pilot production trial runs at its Unit IV from November 25, 2017

Key fundamentals

Evaluate the intrinsic value of Lasa Supergenerics Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 83.7132 96.6762 118.2859 148.6341 158.9171
Liabilities 83.7132 96.6762 118.2859 148.6341 158.9171
Equity 50.1012 50.1012 50.1012 40.6727 40.6727
Gross Profit 6.2659 2.1658 -6.5935 15.6327 47.221
Net Profit -14.7573 -21.7306 -38.6207 -5.3672 22.7777
Cash From Operating Activities -2.8237 2.1387 -17.3004 10.4898 41.3103
NPM(%) -10.35 -20.82 -29.8 -3.91 11.25
Revenue 142.4481 104.335 129.5678 137.1267 202.3795
Expenses 136.1822 102.1692 136.1613 121.494 155.1585
ROE(%) -27.43 -40.4 -71.8 -9.97 42.34

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
16 Sep 2022 0.25 2.5 0 62.35
15 Sep 2021 0.25 2.5 0 73.6

Peers

Other companies within the same industry or sector that are comparable to Lasa Supergenerics Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Sharda Cropchem Ltd 1014.90 -2.98 16.18 68.66 337.37 0.89
Amines and Plasticizers Ltd 149.56 -1.66 24.20 41.87 372.61 0.33
Indogulf Cropsciences Ltd 62.81 -4.52 10.40 37.13 49.78 0.00
Grauer and Weil (India) Ltd 115.60 0.00 37.41 345.05 346.70 0.43

Company Info

Lasa Supergenerics Limited was incorporated as a public limited company on March 11, 2016 (Company Registration Number: 274202 and having Corporate Identification Number: U24233MH2016PLC274202) under the Companies Act, 2013 with the Registrar of Companies, Maharashtra ("RoC") 2021 -LASA launched new product Oxyclozanide Creating new Capacity as a brown field expansion issued by the company.

Lasa Supergenerics Limited was incorporated as a public limited company on March 11, 2016 (Company Registration Number: 274202 and having Corporate Identification Number: U24233MH2016PLC274202) under the Companies Act, 2013 with the Registrar of Companies, Maharashtra ("RoC") 2021 -LASA launched new product Oxyclozanide Creating new Capacity as a brown field expansion issued by the company.

Read More

Parent Organisation

Lasa Supergenerics Ltd.

Founded

11/11/2016

Managing Director

Dr.Omkar Pravin Herlekar

NSE Symbol

LASAEQ

FAQ

The current price of Lasa Supergenerics Ltd is ₹ 7.74.

The 52-week high for Lasa Supergenerics Ltd is ₹ 7.99 and the 52-week low is ₹ 7.48.

The market capitalization of Lasa Supergenerics Ltd is currently ₹ 38.78. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Lasa Supergenerics Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Lasa Supergenerics Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Lasa Supergenerics Ltd shares.

The CEO of Lasa Supergenerics Ltd is Dr.Omkar Pravin Herlekar, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT